Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Chlorhexidine · 1 trial · 4 indications
We will compare the rates of dental implant failure between study arms.
| Arm | Type | Description |
|---|---|---|
| Control | NO_INTERVENTION | This arm will receive standard of care during dental implant insertion. |
| Chlorhexidine | EXPERIMENTAL | Chlorhexidine treatment. |
| Hydrogen Peroxide | EXPERIMENTAL | Hydrogen Peroxide treatment. |
| Name | Type | Description |
|---|---|---|
| Chlorhexidine | DRUG | Chlorhexidine will be inserted into the dental implant internal cavity during dental implant insertion. |
| Hydrogen Peroxide | DRUG | Hydrogen Peroxide will be inserted into the internal cavity of the dental implant during dental implant insertion. |
Inclusion Criteria: * Active duty military * 18-55 years old * Over 6 months remaining at local duty station Exclusion Criteria: * Tobacco user * Medications that affect soft tissue or bone healing * Metabolic disorder that affects soft tissue or bone healing * Active periodontal disease
Chlorhexidine is a small molecule being developed by United Therapeutics Corporation for the treatment of Peri-Implantitis, a condition involving inflammation and infection around dental implants. It is also being studied for related conditions including peri-implant mucositis, implant infection, and dental implant failure. The drug is currently in early Phase 1 clinical development.
Chlorhexidine is an antiseptic agent that targets the microbiome on the internal surface of dental implants. Its mechanism of action involves reducing microbial load to combat peri-implant infections. The drug is being evaluated for its effects on the dental implant internal surface microbiome in patients with peri-implantitis and related conditions.
Chlorhexidine is being developed by United Therapeutics Corporation, a publicly traded company listed on the NASDAQ under the ticker symbol UTHR. The company is conducting clinical research on this small molecule for the treatment of peri-implantitis and related dental implant infections.
Chlorhexidine is in early Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. One clinical trial has been completed, with a total enrollment of 97 participants. The drug is being studied for its antiseptic effects on the dental implant internal surface microbiome.
Chlorhexidine has one completed clinical trial registered under NCT05024760, titled "Antiseptic Effects on the Dental Implant Internal Surface Microbiome." This early Phase 1 study enrolled 97 participants in the United States and included patients with peri-implantitis, peri-implant mucositis, implant infection, and dental implant failure. The trial was randomized and biomarker-selected.